Neuroblastoma

Titilope A. Ishola, Dai H. Chung

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalSurgical Oncology
Volume16
Issue number3
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Neuroblastoma
Tretinoin
Oncogenes
Epigenomics
Therapeutics
Neoplasms

Keywords

  • MYCN
  • Neuroblastoma
  • Tumor regression

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Neuroblastoma. / Ishola, Titilope A.; Chung, Dai H.

In: Surgical Oncology, Vol. 16, No. 3, 01.11.2007, p. 149-156.

Research output: Contribution to journalReview article

Ishola, Titilope A. ; Chung, Dai H. / Neuroblastoma. In: Surgical Oncology. 2007 ; Vol. 16, No. 3. pp. 149-156.
@article{e9768e105074420498484643140ee6ac,
title = "Neuroblastoma",
abstract = "Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.",
keywords = "MYCN, Neuroblastoma, Tumor regression",
author = "Ishola, {Titilope A.} and Chung, {Dai H.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.suronc.2007.09.005",
language = "English (US)",
volume = "16",
pages = "149--156",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Neuroblastoma

AU - Ishola, Titilope A.

AU - Chung, Dai H.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.

AB - Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.

KW - MYCN

KW - Neuroblastoma

KW - Tumor regression

UR - http://www.scopus.com/inward/record.url?scp=36049033401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049033401&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2007.09.005

DO - 10.1016/j.suronc.2007.09.005

M3 - Review article

C2 - 17976976

AN - SCOPUS:36049033401

VL - 16

SP - 149

EP - 156

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 3

ER -